Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
AEON Biopharma, Inc. (AEON)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: AEON (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.2
1 Year Target Price $7.2
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -64.19% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.06M USD | Price to earnings Ratio - | 1Y Target Price 7.2 |
Price to earnings Ratio - | 1Y Target Price 7.2 | ||
Volume (30-day avg) 1 | Beta 0.7 | 52 Weeks Range 0.38 - 115.57 | Updated Date 08/29/2025 |
52 Weeks Range 0.38 - 115.57 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -13.91 |
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.35 | Actual -0.6 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -129.01% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE 1.16 | Enterprise Value 17053536 | Price to Sales(TTM) 97.16 |
Enterprise Value 17053536 | Price to Sales(TTM) 97.16 | ||
Enterprise Value to Revenue 201.68 | Enterprise Value to EBITDA -5.89 | Shares Outstanding 11643800 | Shares Floating 8196294 |
Shares Outstanding 11643800 | Shares Floating 8196294 | ||
Percent Insiders 23.38 | Percent Institutions 12.04 |
Upturn AI SWOT
AEON Biopharma, Inc.
Company Overview
History and Background
AEON Biopharma, Inc. is a biopharmaceutical company focused on developing and commercializing botulinum toxin neurotoxin products for debilitating conditions. The company was founded in 2012 and is headquartered in Newport Beach, California. It is primarily focused on therapeutic indications.
Core Business Areas
- Therapeutic Programs: AEON is focused on therapeutic neurotoxin treatments. Its product candidates are being evaluated in clinical trials for conditions such as cervical dystonia, migraine, and other movement disorders.
Leadership and Structure
Ali Al-Khazali serves as the President and Chief Executive Officer. The company has a board of directors and an executive team focused on research, development, and commercialization.
Top Products and Market Share
Key Offerings
- ABP-450 (prabotulinumtoxinA) Injectable Solution: ABP-450 is AEON's lead product candidate, a botulinum toxin neurotoxin type A being developed for various therapeutic indications, including cervical dystonia and migraine. Currently in clinical trials. Market share is zero as no products are currently FDA approved. Competitors include Allergan (Botox), Ipsen (Dysport), Merz (Xeomin).
Market Dynamics
Industry Overview
The botulinum toxin market is a growing segment of the pharmaceutical industry, driven by increasing demand for therapeutic and aesthetic applications. The market is characterized by established players and emerging companies developing novel formulations and indications.
Positioning
AEON Biopharma is positioned as a clinical-stage company focused on therapeutic applications of botulinum toxin. It is seeking to differentiate itself through its product formulations and target indications.
Total Addressable Market (TAM)
The global botulinum toxin market is estimated to be billions of dollars. AEON Biopharma is aiming to capture a share of this market through its therapeutic programs. The TAM for therapeutics specifically is substantial.
Upturn SWOT Analysis
Strengths
- Proprietary botulinum toxin formulation
- Focus on therapeutic applications
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Clinical stage company with no currently approved products
- Dependent on successful clinical trial outcomes
- Requires significant capital for development and commercialization
- Limited brand recognition compared to established players
Opportunities
- Expansion into new therapeutic indications
- Potential partnerships with larger pharmaceutical companies
- Increasing demand for non-surgical aesthetic treatments
- Growing awareness of botulinum toxin therapeutic benefits
Threats
- Competition from established botulinum toxin manufacturers
- Regulatory hurdles and approval delays
- Adverse events or safety concerns associated with botulinum toxin
- Patent challenges
Competitors and Market Share
Key Competitors
- ABBV
- IPN
- MRZ
Competitive Landscape
AEON Biopharma faces intense competition from established players in the botulinum toxin market. Its success depends on differentiating its product and securing regulatory approvals.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is reflected in the company's progress in advancing its clinical programs.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary depending on the perceived probability of success.
Recent Initiatives: Recent initiatives include advancing clinical trials for ABP-450 in cervical dystonia and migraine.
Summary
AEON Biopharma is a clinical-stage company with no approved products, relying on the success of ABP-450. The company is working toward establishing itself in the botulinum toxin market, but is in a very high growth stage. They face competition from established players like Allergan and Ipsen, and must navigate regulatory hurdles. Its success depends on the clinical trials and partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share figures are estimates and may vary. The AI-based rating is based on available data and algorithms and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AEON Biopharma, Inc.
Exchange NYSE MKT | Headquaters Irvine, CA, United States | ||
IPO Launch date 2021-04-12 | President, CEO & Director Mr. Robert Bancroft | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://www.aeonbiopharma.com |
Full time employees 5 | Website https://www.aeonbiopharma.com | ||
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.